TCM
RPRX icon

TruNorth Capital Management’s Royalty Pharma RPRX Stock Holding History

TruNorth Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-510
Closed -$18K – 326
2025
Q3 		$18K Buy
+510
New +$18.5K ﹤0.01% 298

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TruNorth Capital Management's RPRX Position: Q4 2025 in Review

TruNorth Capital Management sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 510 shares — an estimated $18K sold.

TruNorth Capital Management first reported a position in RPRX in Q3 2025 and held it in 1 quarter. The position peaked at $18K in Q3 2025. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • TruNorth Capital Management reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • TruNorth Capital Management sold 510 Royalty Pharma shares in Q4 2025, an estimated $18K.
  • TruNorth Capital Management first reported a position in Royalty Pharma in Q3 2025 and held it in 1 quarter.
  • TruNorth Capital Management's Royalty Pharma position peaked at $18K in Q3 2025.
  • 539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on TruNorth Capital Management's 13F filing for Q4 2025, filed 11 Feb 2026.